Research programme: lysine specific demethylase 1 and histone deacetylase 6 inhibitors - Jubilant Therapeutics
Alternative Names: LSD1/HDAC6 dual inhibitors - Jubilant TherapeuticsLatest Information Update: 28 Jun 2024
At a glance
- Originator Jubilant Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action HDAC6 protein inhibitors; Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Malignant melanoma; Myelodysplastic syndromes
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
- 28 Jun 2024 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes in USA
- 28 Oct 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA